Scoop: Bing Yao’s ArriVent lining up $145M raise, after $150M debut in 2021
Bing Yao took his previous biotech through three key milestones: IPO, drug approval and an M&A exit. Now, he’s lining up another round of financing for his bet on bringing Chinese R&D to the States.
ArriVent Biopharma debuted with a $150 million round in June 2021. New paperwork filed with the SEC last week outlines a second round of financing is in the works for up to $145 million. The filing documents 17 investors so far lining up $110 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.